Clinical trials
Lymphoproliferative Disorders trials in Italy
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
23 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2007 | 1 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 3 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 7 |
| Recruiting | 6 |
| Terminated | 6 |
| Active, not recruiting | 3 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Amgen Research (Munich) GmbH | 3 |
| Azienda Ospedaliero-Universitaria di Parma | 2 |
| Celgene | 2 |
| Pierre Fabre Medicament | 2 |
| Acerta Pharma BV | 1 |
| Amgen | 1 |
| Ariad Pharmaceuticals | 1 |
| Curis, Inc. | 1 |
| European Association of Urology Research Foundation | 1 |
| European Institute of Oncology | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lymphoproliferative Disorders | 23 |
| Lymphatic Diseases | 12 |
| Immunoproliferative Disorders | 10 |
| Lymphoma | 9 |
| Lymphoma, Non-Hodgkin | 9 |
| Immune System Diseases | 8 |
| Neoplasms | 8 |
| Leukemia | 5 |
| Lymphoma, Large B-Cell, Diffuse | 5 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 |
Trials
Showing 26 to 23 of 23. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.